Supplementary Material for: Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials
Yan Wang(National Institute of Biological Sciences, Beijing), Ning‐Ning Song(Fudan University), Zailong Qin(Guangxi Maternal and Child Health Hospital), Christopher Chen(National University of Singapore), Lin Xu(Guangdong Pharmaceutical University), Xiaoyan Zhou(Shanghai Medical College of Fudan University), Xiangjun Meng, Qing Zhang(First Affiliated Hospital Zhejiang University), Jiahong Xia(Union Hospital)
Cited by 0
Related Papers
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Neuroimaging standards for research into small vessel disease—advances since 2013
|The Lancet Neurology|2023|962
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Vascular dysfunction—The disregarded partner of Alzheimer's disease
|Alzheimer s & Dementia|2019|721